Literature DB >> 31037630

Periostin in Eye Diseases.

Shigeo Yoshida1, Yumi Umeno2, Masatoshi Haruta2.   

Abstract

The transparency of the eye can be disturbed by several eye diseases. It has recently been reported that periostin plays pivotal roles in the pathogenesis of several eye disease, such as diabetic retinopathy (DR), age-related macular degeneration (AMD), glaucoma, pterygia, corneal dystrophy, and chronic ocular allergic diseases. In these diseases, formation of fibro (vascular) tissue plays an important role. Gene expression profiling of human retinal fibro (vascular) membrane revealed significant up-regulation of periostin. The expression of periostin after environmental perturbations, including IL-4 and/or IL-13 induction, can alter normal physiological interactions among fibroblasts, macrophages and ECM protein in the eye. Modulating the expression of periostin by low-molecular weight compounds, antibodies or RNAi directed against the molecule could be a novel therapeutic strategy for inhibiting the progression of those periostin-involved eye diseases.

Entities:  

Keywords:  Age-related macular degeneration; Atopic keratoconjunctivitis; Choroid; Conjunctiva; Cornea; Corneal dystrophy; Epiretinal membranes; Fibrosis; Fibrovascular membranes; Genome-wide gene expression profiling; Glaucoma; IL-13; IL-4; Mouse model of laser-induced choroidal neovascularization; Mouse model of oxygen-induced retinal neovascularization; Neovascularization; Proliferative diabetic retinopathy; Proliferative vitreoretinopathy; Pterygia; Retina; Serum; Single-stranded RNA interference; Tear; Vitreoretinal disease

Mesh:

Substances:

Year:  2019        PMID: 31037630     DOI: 10.1007/978-981-13-6657-4_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients.

Authors:  Yue Xu; Chi Xie; Yan Fang; Yan Yu; Cui Qiu
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

2.  Assessment of circulating fibrotic proteins (periostin and tenascin -C) In Type 2 diabetes mellitus patients with and without retinopathy.

Authors:  A Indumathi; Gandhipuram Periyaswamy Senthilkumar; Kuppuswamy Jayashree; K Ramesh Babu
Journal:  Endocrine       Date:  2022-03-10       Impact factor: 3.925

Review 3.  Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives.

Authors:  Louis Tenbrock; Julian Wolf; Stefaniya Boneva; Anja Schlecht; Hansjürgen Agostini; Peter Wieghofer; Günther Schlunck; Clemens Lange
Journal:  Cell Tissue Res       Date:  2021-09-03       Impact factor: 5.249

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.